Evidence map›Paper›PMID 41957308›Full record

ReviewAmerican journal of clinical dermatology2026

The Impact of GLP-1 Receptor Agonists on Hair: Beneficial Effects or Adverse Outcomes?

S Morteza Seyed Jafari, Gemma Caro, Shari R Lipner, Matilde Iorizzo

Abstract readReview
PubMed Publisher
In one paragraph

Review in American journal of clinical dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

S Morteza Seyed JafariDepartment of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. morteza.jafari@insel.ch.ORCID http://orcid.org/0000-0002-6466-2199
Gemma CaroDepartment of Dermatology, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Shari R LipnerDepartment of Dermatology, Weill Cornell Medicine, New York, NY, USA.
Matilde IorizzoPrivate Dermatology Practice, Lugano/Bellinzona, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the treatment of type II diabetes and obesity. Since their introduction, studies continue to reveal their beneficial effects in a range of other conditions. However, hair loss associated with GLP-1RAs is still a controversial topic. This narrative review explores the current evidence linking GLP-1RAs to hair-related conditions because, while some studies have reported hair regrowth in patients with androgenetic alopecia and a decrease in inflammatory infiltrate in patients with cicatricial alopecia, many more have suggested association with telogen effluvium. Given the heterogeneity of current reports, careful clinical evaluation, monitoring weight trends, and assessing relevant laboratory parameters is recommended. Prospective, controlled studies, including immunohistochemical or molecular profiling of GLP-1 receptor expression in human hair follicles, are necessary to better clarify the potential role of GLP-1RAs in hair biology, to inform safe prescribing practices and to avoid discontinuation of a beneficial treatment.

Indexed as

AlopeciaDiabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsHairHypoglycemic AgentsGlucagon-Like Peptide-1 ReceptorHair FollicleHumansObesitySemaglutideTreatment OutcomeGLP1R protein, humanGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsSemaglutide

Identifiers

PMID41957308

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.